Sunshine Biopharma Inc - SBFM STOCK NEWS

Sunshine Biopharma, Inc. (SBFM, SBFMW) announced a securities purchase agreement generating approximately $8.0 million from institutional and accredited investors. The offering involves 3,603,604 units priced at $2.22 each, with each unit consisting of a share of common stock and a non-tradable warrant. The closing is expected around March 14, 2022. Sunshine Biopharma is developing treatments for COVID-19 and various cancers, including its lead compound SBFM-PL4 and anticancer drug Adva-27a, with clinical trials planned in collaboration with prestigious institutions.

Sunshine Biopharma has announced an agreement with the University of Arizona to advance the development of novel PLpro inhibitors. These inhibitors aim to combat SARS-CoV-2 by determining safety and efficacy in preclinical models, specifically MA10 mice. The lead compound, SBFM-PL4, is also undergoing further development at the University of Georgia. The initiative is a crucial step in enhancing treatment options against COVID-19, as highlighted by the company's CEO, Dr. Steve Slilaty.

Aegis Capital Corp. acted as the sole bookrunner for Sunshine Biopharma Inc.'s $8 million underwritten public offering, aimed at supporting the development of its COVID-19 therapeutic SBFM-PL4 and anticancer compound Adva-27a. Sunshine Biopharma is focused on creating treatments for COVID-19 and aggressive forms of cancer, including pancreatic cancer. The company is moving forward with clinical trials for Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells. This offering could potentially enhance Sunshine Biopharma's financial position as it seeks to progress its research and development initiatives.

Sunshine Biopharma announced the completion of its public offering of 1,882,353 units at $4.25 each, raising $8 million in gross proceeds. Each unit comprises one share of common stock and two warrants, both exercisable at $4.25. Aegis Capital Corp. managed the offering and was granted a 45-day option to purchase additional securities. The company is advancing SBFM-PL4, a lead compound for COVID-19 treatment, and preparing for clinical trials of Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells.

Sunshine Biopharma, focused on oncology and antiviral drug development, has priced its public offering of 1,882,353 units at $4.25 each, totaling $8 million. Each unit comprises one share of common stock and two warrants, immediately separable for trading. Aegis Capital is the sole book-running manager and holds a 45-day option for an additional 15% of shares and warrants. The offering will close around February 17, 2022. Sunshine Biopharma's common stock and warrants have been approved for listing on the Nasdaq under symbols SBFM and SBFMW.

On December 20, 2021, Sunshine Biopharma (SBFM) issued 2,904,833 shares of Common Stock to RB Capital, converting $1,361,000 in convertible debt at an average price of $0.47 per share. The remaining convertible debt totals $1,900,000 at an average conversion price of $0.30, with maturity dates in 2023. This move is expected to enhance the company's financial position while conserving cash for ongoing research in antiviral and anticancer drug development. Key projects include SBFM-PL4, a potential COVID-19 treatment, and Adva-27a, targeting multidrug-resistant cancers.

Sunshine Biopharma (OTC PINK: SBFM) has expanded its board from three to five members by appointing three new independent directors: Andrew Tesley, JD Kish, and Dr. Rabi Kiderchah. This strategic move is part of the company's application process to uplist to Nasdaq. The new directors bring valuable expertise in legal, accounting, and medical fields. Mr. Camille Sebaaly has resigned as a director but will continue as CFO. Sunshine Biopharma is advancing treatments for COVID-19 and cancer, including ongoing studies on potential inhibitors of SARS-CoV-2 and the anticancer drug Adva-27a.

Sunshine Biopharma (SBFM) has filed a patent application for a novel treatment targeting neurodegenerative disorders. This application, dated October 1, 2021, presents data indicating that specific mRNA molecules can protect neuronal cells from oxidative stress, a condition mimicking neuronal degeneration. Neurodegenerative diseases affect millions globally, with no known cures. The company aims to develop a therapeutic approach that could potentially alleviate symptoms and halt disease progression.

Sunshine Biopharma (SBFM) announced significant advancements in its drug development for COVID-19 and cancer therapies. The company mapped mutations from Delta and other variants, finding that most mutations affect the Spike protein, leaving their PLpro inhibitors likely effective against ongoing variants. The lead compound, SBFM-PL4, is being tested in mice engineered to be susceptible to SARS-CoV-2. Additionally, Sunshine Biopharma is progressing with Adva-27a, an anticancer compound, demonstrating effectiveness against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned.